# Intensity Therapeutics, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Intensity Therapeutics, Inc). ## Overview Intensity Therapeutics, Inc. is a clinical-stage biotechnology company developing intratumoral cancer therapies designed to be injected directly into tumors. Its lead candidate, INT230-6, combines two cytotoxic agents with a proprietary amphiphilic molecule to help the drugs spread within the tumor and enter cancer cells. ## Products & services • INT230-6 intratumoral oncology candidate • INVINCIBLE-3 clinical study • INVINCIBLE-4 clinical study • GMP manufacturing of product candidates and enhancer molecules • Regulatory, clinical development, and commercialization preparation - **Lead product candidate** (90%) — INT230-6 is the company's main intratumoral oncology therapy under clinical development. - **Clinical development programs** (5%) — INVINCIBLE-3 and INVINCIBLE-4 are the core studies advancing the lead candidate. - **Manufacturing and CMC activities** (5%) — GMP batch production, labeling, stability testing, and related supply work for trials. - INT230-6, a direct-injection intratumoral cancer therapy - INVINCIBLE-3 clinical study for INT230-6 - INVINCIBLE-4 clinical study for INT230-6 - GMP batches of product candidates and enhancer molecules - Clinical development, regulatory filing, and commercialization readiness ## Customers The company does not yet sell products and has not generated revenue from product sales or licensing. Its near-term 'customers' are clinical trial sites, investigators, regulators, and eventually oncology patients and treating physicians if INT230-6 is approved. Any future commercial buyers would likely include hospitals, cancer centers, and payers supporting oncology treatment access. - **Clinical trial sites and investigators** (primary) — They administer the studies, collect data, and generate the evidence needed for regulatory approval. - **Oncology patients** (primary) — Patients with solid tumors are the intended end users of the intratumoral therapy in trials and, later, commercialization. - **Regulators** (primary) — FDA and other agencies determine whether the product can advance from trials to marketing approval. - **Hospitals and cancer centers** (emerging) — These would be the main institutional buyers if the therapy reaches market and is adopted in oncology practice. - Clinical trial investigators running INVINCIBLE studies - Cancer patients enrolled in trials of INT230-6 - Regulators reviewing safety and efficacy data - Hospitals and oncology centers if the drug is approved - Payers and health systems that would evaluate reimbursement ## Geography The company is based in the United States and its operations are centered on U.S.-based clinical development, manufacturing, and capital markets access. The filings do not disclose meaningful country revenue because the company has not generated product revenue. Geography matters mainly through U.S. regulatory oversight, domestic trial execution, and exposure to U.S. tariff and import/export policy for clinical supply chains. - United States is the operating base and primary market for trials - No product revenue disclosed to date, so no country sales mix exists - U.S. FDA pathway is central to future commercialization - Clinical manufacturing and supply chain activity may cross borders - Tariff and import/export policy could affect trial materials and costs ## Strategy Intensity Therapeutics is focused on funding and advancing its INVINCIBLE-3 and INVINCIBLE-4 studies, while building the manufacturing, regulatory, and organizational infrastructure needed for approval. The company also needs to preserve intellectual property and prepare a future commercial platform, but its strategy remains dependent on external financing until any product reaches market. - **Advance clinical trials** (short-term) — Clinical proof-of-concept is the main value driver for a pre-revenue biotech company. - **Secure manufacturing supply** (short-term) — GMP batches and stability testing are required to support ongoing trials and future approval. - **Prepare for regulatory and commercial launch** (medium-term) — Approval and eventual launch require regulatory filings, sales capability, and medical affairs readiness. - Fund INVINCIBLE-3 and INVINCIBLE-4 clinical studies - Produce additional GMP batches of product candidates and enhancers - Pursue regulatory approvals after successful clinical results - Expand personnel and operating systems - Build IP protection and future commercial infrastructure ## Risks The company is highly dependent on clinical success, regulatory approval, and the ability to raise capital before any product revenue exists. It also faces typical biotech risks such as trial delays, manufacturing complexity, IP protection, and commercialization uncertainty, plus the specific risk of Nasdaq listing compliance and policy changes affecting imports and tariffs. - **Clinical development failure** [critical] — INT230-6 must show safety and efficacy in trials before it can generate revenue. - **Financing risk** [critical] — The company expects to fund operations through equity, debt, or collaborations until commercialization. - **Regulatory approval risk** [high] — Even successful trials may not translate into marketing approval or commercial launch. - **Nasdaq delisting risk** [high] — Failure to regain compliance with listing standards could reduce liquidity and capital access. - **Trade policy and tariff risk** [medium] — Clinical and manufacturing inputs may be affected by import/export rules and tariffs. - No product revenue yet, so survival depends on external financing - Clinical trials may fail, delay, or produce insufficient efficacy data - Regulatory approval is uncertain and may never be obtained - Nasdaq minimum bid price compliance could lead to delisting - Tariff and import/export changes may raise supply chain costs ## Accounting As a pre-revenue biotech, the most important accounting issue is that research and development costs are expensed as incurred, so trial and manufacturing activity directly drives reported losses. Investors should also watch stock-based compensation, warrant accounting, and fair-value treatment of financing instruments, since recent offerings and ATM sales can materially affect dilution and period results. - **Research and development expense recognition** — Directly affects operating loss and cash burn - **Stock-based compensation** — Affects reported operating expense and share count - **Equity financing and warrant accounting** — Affects equity balances and per-share metrics - R&D expense timing drives reported losses as trials and manufacturing ramp - Clinical trial and CRO costs are expensed as incurred - Stock-based compensation can be a meaningful non-cash expense - Warrants and equity offerings can affect dilution and fair value estimates - Emerging growth company status may affect timing of new accounting standards --- *Last updated: 2026-09-24T12:34:56.105336+00:00*